SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT02961270

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Clinical Activity of Icotinib in Patients With Advanced Non-small-cell Lung Cancer Harbouring Uncommon EGFR Mutations: a Single-arm, Prospective, Phase 2 Study

This study aims to evaluate the efficacy of icotinib, a first generation EGFR TKI, in non-small cell lung cancer patients harboring uncommon EGFR mutation

NCT02961270 Non-small Cell Lung Cancer
MeSH: Lung Neoplasms Carcinoma, Non-Small-Cell Lung
HPO: Neoplasm of the lung Non-small cell lung carcinoma

1 Interventions

Name: Icotinib

Description: Icotinib will be given orally 250 mg thrice per day until disease progression, or untolerated toxicity

Type: Drug

icotinib


Primary Outcomes

Measure: progression-free survival

Time: 10 months

Secondary Outcomes

Measure: tumor response rate

Time: 2 months

Measure: overall survival

Time: 24 months

Purpose: Treatment

Single Group Assignment


There is one SNP

SNPs


1 L858R

Inclusion Criteria: - Patients with stage IIIB/IV non-small cell lung cancer - Patients with uncommon epidermal growth factor receptor (EGFR) mutation - Targeted-therapy-naive patients - Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2 - Evaluable target lesions according to RECIST 1.1 for tumour response assessment Exclusion Criteria: - Wild-type EGFR - Positive 19 del and/or 21 L858R mutation - Previous treatment with EGFR TKIs such as gefitinib, erlotinib, and afatinib - Patients who have documented history of interstitial lung disease Inclusion Criteria: - Patients with stage IIIB/IV non-small cell lung cancer - Patients with uncommon epidermal growth factor receptor (EGFR) mutation - Targeted-therapy-naive patients - Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2 - Evaluable target lesions according to RECIST 1.1 for tumour response assessment Exclusion Criteria: - Wild-type EGFR - Positive 19 del and/or 21 L858R mutation - Previous treatment with EGFR TKIs such as gefitinib, erlotinib, and afatinib - Patients who have documented history of interstitial lung disease Non-small Cell Lung Cancer Lung Neoplasms Carcinoma, Non-Small-Cell Lung null --- L858R ---

Inclusion Criteria: - Patients with stage IIIB/IV non-small cell lung cancer - Patients with uncommon epidermal growth factor receptor (EGFR) mutation - Targeted-therapy-naive patients - Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2 - Evaluable target lesions according to RECIST 1.1 for tumour response assessment Exclusion Criteria: - Wild-type EGFR - Positive 19 del and/or 21 L858R mutation - Previous treatment with EGFR TKIs such as gefitinib, erlotinib, and afatinib - Patients who have documented history of interstitial lung disease Inclusion Criteria: - Patients with stage IIIB/IV non-small cell lung cancer - Patients with uncommon epidermal growth factor receptor (EGFR) mutation - Targeted-therapy-naive patients - Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2 - Evaluable target lesions according to RECIST 1.1 for tumour response assessment Exclusion Criteria: - Wild-type EGFR - Positive 19 del and/or 21 L858R mutation - Previous treatment with EGFR TKIs such as gefitinib, erlotinib, and afatinib - Patients who have documented history of interstitial lung disease Non-small Cell Lung Cancer Lung Neoplasms Carcinoma, Non-Small-Cell Lung null --- L858R --- --- L858R ---



HPO Nodes


HPO:
Neoplasm of the lung
Genes 61
REST GPC3 WT1 HPGD BRAF PIK3CA TP53 TRIM28 RB1 TRIP13 SLCO2A1 AKT1 CASP8 KRAS TSC1 POU6F2 EWSR1 PRKN LMNA NAB2 TERT TSC2 SLC22A18 BRCA2 PPP2R1B STAT6 STK11 MUC5B ERBB2 TSC2 MBTPS2 BAP1 TSC2 DICER1 PDGFRB PERP EGFR TSC1 DIS3L2 NOTCH3 KEAP1 DICER1 DICER1 WT1 TSC1 C11ORF95 IRF1 CYP2A6 WRN RELA WT1 PTEN SFTPC SFTPA2 ERCC6 TRPV3 TP53 H19 TRIM28 FASLG MAP3K8
Non-small cell lung carcinoma
Genes 3
TP53 TP53 BAP1